Hypomethylation and the Resultant Overexpressed PARM1: a Biomarker for Poor Prognosis of Diffuse Large B-cell Lymphoma

被引:0
|
作者
Cao, Baoping [1 ]
Guo, Xiaochuan [1 ]
Wang, Bin [1 ]
Wang, Weixia [1 ]
Han, Dong [1 ]
Zhang, Weijing [1 ]
Zhong, Kaili [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Lymphoma, Beijing 100038, Peoples R China
关键词
WEB SERVER; CANCER; AUTOPHAGY; INHIBITION; RESISTANCE; PROLIFERATION; MUCINS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate androgen-regulated mucin-like protein (PARM1) is known to promote cell survival via protecting the cell surface, thus being involved in cancer development. The Gene Expression Profiling Interactive Analysis (GEPIA), MEXPRESS database, LinkedOmics database, GeneMANIA database, and the Tumor Immune Estimation Resource (TIMER) database were accessed to explore the epigenetic regulation, prognostic value, biological functions and mechanisms of PARM1 in diffuse large B-cell lymphoma (DLBCL). Hypomethylation and resultant overexpression of PARM1 was found in DLBCL. The high-level expression of PARM1 was related to the poor outcome of DLBCL patients. PARM1 participated in DNA repair, cell cycle, and cellular response to stress. PARM1 was also associated with autophagy, apoptosis, Ras pathway, and MAPK cascade. Significant kinase targets of PARM1 included ATM, CDK1, and CDK2. Significant transcription factor targets of PARM1 involved ELK1, MYC and so on. Significant miRNA targets of PARM1 included miR21, miR202, miR323, and miR345. Further analysis suggested that the PARM1 regulated autophagy through the PI3K-Akt signaling. PARM1 was found to be correlated with immune cell infiltration, which indicated the important roles of PARM1 in microenvironment of DLBCL. Our study lays a foundation for further research on the impact of PARM1 in DLBCL tumorigenesis and precision therapy.
引用
收藏
页码:27 / 40
页数:14
相关论文
共 50 条
  • [31] The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma
    Xiong, Wenjing
    Li, Liru
    Hui, Xue
    Liu, Yue
    Li, Hongbin
    Zhang, Yue
    Zhao, Shu
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09): : 2240 - 2249
  • [33] Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma
    Zhou, Weiling
    Li, Weijing
    He, Cuiying
    Ma, Ruijuan
    Gao, Qian
    Wang, Yuan
    Feng, Lei
    Liu, Lihong
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGET & THERAPY, 2022, 15 : 2039 - 2049
  • [34] Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis
    Cioroianu, Alexandra Ioana
    Stinga, Patricia Irina
    Sticlaru, Liana
    Cioplea, Mirela Daniela
    Nichita, Luciana
    Popp, Cristiana
    Staniceanu, Florica
    ANALYTICAL CELLULAR PATHOLOGY, 2019, 2019
  • [35] Prognosis of diffuse large B-cell lymphoma: 16 years of experience
    Esin, E.
    Saglam, A.
    Hayran, M.
    Uner, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] MicroRNAs implicated in canine diffuse large B-cell lymphoma prognosis
    Elshafie, Nelly O.
    Gribskov, Michael
    Lichti, Nathanael I.
    Sayedahmed, Ekramy E.
    Childress, Michael O.
    dos Santos, Andrea Pires
    FEBS OPEN BIO, 2024, 14 (11): : 1899 - 1913
  • [37] Diffuse large B-cell lymphoma
    Barraclough, Allison
    Hawkes, Eliza
    Sehn, Laurie H.
    Smith, Sonali M.
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [38] Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Salles, Gilles
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 842 - 858
  • [39] Diffuse large B-cell lymphoma
    Li, Shaoying
    Young, Ken H.
    Medeiros, L. Jeffrey
    PATHOLOGY, 2018, 50 (01) : 74 - 87
  • [40] Diffuse large B-cell lymphoma
    Hunt, Kristin E.
    Reichard, Kaaren K.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (01) : 118 - 124